Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar brought to you by IsoPlexis, Katie McKenna will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.
Topics to be covered
Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
Assessing T cell functionality with single-cell proteomics
Tuesday, April 27, 2021
2:30 - 3:30 PM Eastern Time
Meet the speaker
Katie McKenna, PhD Postdoctoral Fellow Center for Cell and Gene Therapy Baylor College of Medicine Texas Children’s Hospital Methodist Hospital
Register Now
Harnessing Single-Cell Multi-Omic Energy States for Integrated Cancer Biology Feb 16, 2021
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
